Coya Therapeutics (NASDAQ:COYA) Earns “Buy” Rating from D. Boral Capital

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating restated by stock analysts at D. Boral Capital in a note issued to investors on Friday,Benzinga reports. They currently have a $15.00 price target on the stock. D. Boral Capital’s price target would indicate a potential upside of 259.71% from the company’s current price.

COYA has been the subject of a number of other research reports. HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of Coya Therapeutics in a research note on Monday, March 23rd. Wall Street Zen downgraded Coya Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Wednesday, January 21st. Finally, Chardan Capital reissued a “buy” rating and set a $14.00 target price on shares of Coya Therapeutics in a research report on Monday, March 16th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Coya Therapeutics Price Performance

Shares of COYA opened at $4.17 on Friday. The stock has a 50-day moving average of $4.55 and a 200-day moving average of $5.33. The company has a market cap of $97.83 million, a PE ratio of -3.28 and a beta of 0.51. Coya Therapeutics has a one year low of $3.71 and a one year high of $7.75.

Coya Therapeutics (NASDAQ:COYA) last issued its earnings results on Monday, March 16th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.26). The firm had revenue of $3.96 million during the quarter, compared to analyst estimates of $1.93 million. Coya Therapeutics had a negative net margin of 267.13% and a negative return on equity of 62.76%. Analysts expect that Coya Therapeutics will post -1.15 EPS for the current fiscal year.

Institutional Investors Weigh In On Coya Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. XTX Topco Ltd bought a new stake in Coya Therapeutics during the 4th quarter valued at $192,000. Occudo Quantitative Strategies LP bought a new stake in Coya Therapeutics during the 4th quarter valued at $66,000. Millennium Management LLC bought a new stake in Coya Therapeutics during the 4th quarter valued at $121,000. 683 Capital Management LLC bought a new stake in Coya Therapeutics during the 4th quarter valued at $465,000. Finally, Cetera Investment Advisers bought a new stake in Coya Therapeutics during the 4th quarter valued at $128,000. Institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.